Study guide
14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)
ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring
1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal
2 Chapter 2: Assessment Foundations & Lifespan Considerations
2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)
3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation
3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles
4 Chapter 4: Cardiovascular Disorders
4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease
5 Chapter 5: Respiratory Disorders
5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules
6 Chapter 6: HEENT & Allergic/Immunologic Disorders
6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency
7 Chapter 7: Endocrine & Metabolic Disorders
7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism
8 Chapter 8: Gastrointestinal & Hepatic Disorders
8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening
9 Chapter 9: Renal, Urological & Men's Health
9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction
10 Chapter 10: Musculoskeletal & Rheumatologic Disorders
10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes
11 Chapter 11: Neurological & Psychiatric Disorders
11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care
12 Chapter 12: Dermatologic, Hematologic & Infectious Disease
12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies
13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care
13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions
14 Chapter 14: Gynecologic & Women's Health
14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)
15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination
15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment
16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement
16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics
14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)
Key Takeaways Explain This Topic AI
Vaginal infections are differentiated by physical characteristics, microscopic analysis, and pH: Bacterial Vaginosis (Amsel criteria: homogeneous thin grey discharge, pH >4.5, positive whiff test, >20% clue cells, absence of WBCs; treated with metronidazole 500 mg PO BID x 7 days); Vulvovaginal Candidiasis (thick white curd-like discharge, pH <4.5, hyphae/pseudohyphae; treated with fluconazole 150 mg PO); Trichomoniasis (frothy green discharge, strawberry cervix, pH >4.5, motile trichomonads and prominent PMNs on wet mount/NAAT; treated with metronidazole 500 mg PO BID x 7 days with mandatory partner treatment).
Pelvic Inflammatory Disease (PID) is diagnosed clinically in sexually active women with lower abdominal/pelvic pain and at least ONE bimanual minimum criterion: cervical motion tenderness ('chandelier sign'), uterine tenderness, or adnexal tenderness; outpatient therapy requires Ceftriaxone 500 mg IM single dose PLUS Doxycycline 100 mg PO BID x 14 days PLUS Metronidazole 500 mg PO BID x 14 days, with mandatory 48-72 hour re-evaluation.
Abnormal Uterine Bleeding (AUB) is categorized by the FIGO PALM-COEIN classification (Structural: Polyp, Adenomyosis, Leiomyoma, Malignancy; Non-structural: Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not classified); postmenopausal bleeding is endometrial adenocarcinoma until proven otherwise and requires urgent transvaginal ultrasound (TVUS) and/or endometrial biopsy.
On transvaginal ultrasound for postmenopausal uterine bleeding, an endometrial stripe thickness (EMT) ≤4 mm carries a >99% negative predictive value for endometrial cancer; an EMT >4 mm or persistent bleeding requires gold-standard office Pipelle Endometrial Biopsy (EMB).
USPSTF/ASCCP cervical cancer screening guidelines mandate cytology alone every 3 years for ages 21–29; for ages 30–65, options include high-risk HPV (hrHPV) alone every 5 years, hrHPV + cytology co-testing every 5 years, or cytology alone every 3 years; screening terminates at age 65 after adequate prior negative screening and no history of CIN 2+ in the preceding 25 years.
Last updated: August 2026
Gynecologic Infections, Abnormal Uterine Bleeding & Cervical Cancer Screening
Gynecologic complaints represent a major portion of primary care visits across the adult-gerontology spectrum. The AGPCNP must achieve mastery in distinguishing benign vaginal dysbiosis from invasive sexually transmitted infections, executing acute outpatient management for pelvic inflammatory disease, applying the FIGO PALM-COEIN classification to abnormal uterine bleeding, and navigating the 2019/2020 ASCCP risk-based guidelines for cervical cancer prevention.
1. Vaginal Ecology & Vaginitis Differential Diagnosis
The normal healthy vaginal ecosystem is dominated by hydrogen peroxide- and lactic acid-producing Lactobacillus species ( L. crispatus , L. jensenii ), which maintain an acidic vaginal pH \text{pH} pH of 3.8 to 4.5 3.8\text{ to }4.5 3.8 to 4.5 . When this microenvironment is disrupted, pathological overgrowth or infectious vaginitis occurs. +---------------------------------------------------------------------------------------------------+
- | DIAGNOSTIC TRIAD OF INFECTIOUS VAGINITIS |
- | |
- | FEATURE BACTERIAL VAGINOSIS (BV) CANDIDIASIS (VVC) TRICHOMONIASIS |
- | --------------------------------------------------------------------------------------------- |
- | Etiology Polymicrobial dysbiosis Candida albicans (85-90%) Trichomonas vaginalis |
- | (Gardnerella, Atopobium, Candida glabrata (10-15%) (Flagellated protozoan|
- | Prevotella, Mobiluncus) - Sexually Transmitted|
- | |
- | Discharge Thin, homogeneous, off- Thick, white, clumpy, Copious, frothy, |
- | white/gray, adherent "cottage cheese"-like yellow-green, malodor |
- | |
- | Symptoms Fishy malodor; mild Intense vulvar pruritus, Severe vulvar itching,|
- | discharge; NO dyspareunia burning, dysuria, redness dyspareunia, dysuria |
- | |
- | Vaginal pH ELEVATED: >4.5 NORMAL: 3.8 - 4.5 ELEVATED: >4.5 (5-7) |
- | |
- | 10% KOH Whiff Test POSITIVE (Strong amine NEGATIVE OFTEN POSITIVE |
- | fishy odor) (Mild amine odor) |
- | |
- | Microscopy CLUE CELLS (>20% squamous Pseudohyphae & budding MOTILE TRICHOMONADS |
- | (Wet Mount) cells coated by coccobacilli; yeast spores on KOH; with flagella; |
- | NO white blood cells/PMNs) Rare WBCs NUMEROUS PMNs / WBCs |
- | |
- | Physical Signs No mucosal inflammation Vulvar erythema, edema, "Strawberry Cervix" |
- | fissures, excoriations (colpitis macularis) |
- +---------------------------------------------------------------------------------------------------+
- A. Bacterial Vaginosis (BV)
Diagnostic Framework (Amsel Criteria): Diagnosis requires ≥ 3 of the following 4 criteria \ge 3\text{ of the following 4 criteria} ≥ 3 of the following 4 criteria :
Homogeneous, thin, off-white/gray discharge that smoothly coats the vaginal walls.
Vaginal pH > 4.5 \text{pH} > 4.5 pH > 4.5 .
Positive Whiff-Amine test (release of volatile putrescine/cadaverine fishy odor upon adding 1 drop of 10% KOH to discharge).
Presence of Clue Cells on saline wet mount (vaginal epithelial cells whose borders are completely obscured/stippled by adherent coccobacilli, accounting for > 20 % >20\% > 20% of all epithelial cells).
Gold Standard: Nugent scoring of Gram stain (evaluates morphotypes: loss of Gram-positive Lactobacillus rods and predominance of Gram-negative/variable rods).
CDC Recommended Treatment:
- Metronidazole 500 mg orally twice daily for 7 days (First-Line Gold Standard); OR
- Metronidazole 0.75% gel 5 g intravaginally once daily at bedtime for 5 days; OR
Clindamycin 2% cream 5 g intravaginally at bedtime for 7 days.
Clinical Pearl: Alcohol abstinence during oral metronidazole and for ≥ 24 hours \ge 24\text{ hours} ≥ 24 hours after completion is essential to prevent severe disulfiram-like reactions (nausea, vomiting, flushing, tachycardia). Routine treatment of male sexual partners is not recommended .
B. Vulvovaginal Candidiasis (VVC)
Diagnostic Confirmation: Saline or 10% KOH wet mount demonstrates fungal elements (pseudohyphae and budding blastospores). Vaginal pH \text{pH} pH remains acidic and normal ( < 4.5 <4.5 < 4.5 ).
Classification & Treatment:
Uncomplicated VVC (Sporadic, mild-to-moderate, C. albicans, immunocompetent):
Fluconazole (Diflucan) 150 mg single oral dose; OR
Intravaginal azoles (e.g., Clotrimazole 1% cream or Miconazole 200 mg suppository daily x 3 days).
Complicated / Recurrent VVC ( ≥ 4 episodes/year \ge 4\text{ episodes/year} ≥ 4 episodes/year , severe erythema/fissuring, uncontrolled diabetes, immunosuppression):
Fluconazole 150 mg orally every 72 hours for 3 doses (Days 1, 4, and 7), followed by weekly maintenance Fluconazole 150 mg orally for 6 months .
Non-albicans Candida (e.g., Candida glabrata - azole resistant):
Boric acid gelatin capsules 600 mg intravaginally daily at bedtime for 14 days (Toxic if swallowed orally!).
C. Trichomoniasis
Etiology & Transmission: Trichomonas vaginalis , a flagellated, anaerobic, parasitic protozoan. It is a sexually transmitted infection (STI) associated with enhanced HIV transmission and preterm labor.
Diagnostics: Wet mount shows motile, flagellated oval organisms and abundant polymorphonuclear leukocytes (PMNs). However, wet mount sensitivity is only 50–60%; Nucleic Acid Amplification Testing (NAAT) is the diagnostic gold standard ( > 95 % >95\% > 95% sensitivity).
Updated CDC Treatment Guidelines:
Women: Metronidazole 500 mg orally twice daily for 7 days (Multi-dose oral therapy has significantly higher cure rates than single-dose 2 g in women).
Men: Metronidazole 2 g orally in a single dose.
Mandatory Partner Management: Sexual partner(s) MUST be treated concurrently, and sexual intercourse avoided until both partners complete therapy and symptoms resolve. Retest all patients with NAAT at 3 months post-treatment.
2. Pelvic Inflammatory Disease (PID) & Tubo-Ovarian Abscess (TOA)
PID represents an acute, ascending polymicrobial infection of the upper female genital tract (endometrium, fallopian tubes, ovaries, and pelvic peritoneum). +---------------------------------------------------------------------------------------------------+
- | CDC CLINICAL DIAGNOSTIC CRITERIA FOR PID |
- | |
- | [MINIMUM CLINICAL CRITERIA (Presumptive Diagnosis)] |
- | In a sexually active female at risk for STIs presenting with lower abdominal or pelvic pain, |
- | initiate empiric treatment if AT LEAST ONE of the following is present on bimanual exam: |
- | 1. CERVICAL MOTION TENDERNESS ("Chandelier Sign") |
- | 2. UTERINE TENDERNESS |
- | 3. ADNEXAL TENDERNESS (Unilateral or Bilateral) |
- | (In the absence of any other identified etiology). |
- | | |
- | v |
- | [ADDITIONAL SUPPORTING CRITERIA (Enhance Diagnostic Specificity)] |
- | - Oral temperature >38.3°C (>101.0°F) |
- | - Abnormal cervical or vaginal mucopurulent discharge or cervical friability |
- | - Abundant white blood cells (WBCs) on saline wet mount of vaginal fluid |
- | - Elevated Erythrocyte Sedimentation Rate (ESR) or C-Reactive Protein (CRP) |
- | - Laboratory documentation of cervical infection with N. gonorrhoeae or C. trachomatis |
+---------------------------------------------------------------------------------------------------+ +---------------------------------------------------------------------------------------------------+
- | CDC EMPIRIC TREATMENT PROTOCOLS FOR PID |
- | |
- | OUTPATIENT ORAL / INTRAMUSCULAR REGIMEN: |
- | 1. CEFTRIAXONE: 500 mg IM in a single dose (1,000 mg if patient weight ≥150 kg) |
- | PLUS |
- | 2. DOXYCYCLINE: 100 mg orally twice daily for 14 FULL DAYS |
- | PLUS |
- | 3. METRONIDAZOLE: 500 mg orally twice daily for 14 FULL DAYS |
- | (Metronidazole added to ensure anaerobic coverage and treat concomitant BV / Trichomonas) |
- | |
- | MANDATORY OUTPATIENT RE-EVALUATION: |
- | - Patient MUST be clinically re-evaluated within 48 to 72 hours. |
- | - If no substantial clinical improvement (reduction in pain, fever, tenderness), the patient |
- | MUST BE HOSPITALIZED for inpatient parenteral therapy and pelvic ultrasound imaging. |
- | |
- | CRITERIA MANDATING INPATIENT HOSPITALIZATION FOR PID: |
- | - Surgical emergencies cannot be excluded (e.g., Acute Appendicitis) |
- | - Suspected Tubo-Ovarian Abscess (TOA) on ultrasound |
- | - Pregnancy |
- | - Severe illness, high fever (>38.5°C), nausea, intractable vomiting, or peritonitis |
- | - Inability to tolerate or adhere to outpatient oral antimicrobial regimen |
- | - Lack of clinical response to outpatient therapy within 72 hours |
- +---------------------------------------------------------------------------------------------------+
- Long-Term PID Sequelae
Tubal Factor Infertility: Occurs in 8% after 1 episode of PID, 20% after 2 episodes, and > 40 % >40\% > 40% after 3+ episodes due to post-inflammatory tubal scarring and occlusion.
Ectopic Pregnancy: Relative risk increases 7- to 10-fold following salpingitis.
Chronic Pelvic Pain: Develops in ~30% due to dense pelvic adhesions.
Fitz-Hugh-Curtis Syndrome (Perihepatitis): Inflammation of the hepatic capsule with "violin-string" adhesions between the liver surface and anterior abdominal wall, presenting as sharp right upper quadrant (RUQ) pleuritic pain mimicking acute cholecystitis.
3. Abnormal Uterine Bleeding (AUB) & FIGO Classification
Abnormal Uterine Bleeding in non-pregnant reproductive-age women is standardized under the FIGO PALM-COEIN classification system: +---------------------------------------------------------------------------------------------------+
- | FIGO PALM-COEIN CLASSIFICATION FOR AUB |
- | |
- | [STRUCTURAL CAUSES (PALM) - Measured by Imaging / Histopathology] |
- | P - POLYP -> Endometrial or endocervical polyps; intermenstrual spotting |
- | A - ADENOMYOSIS -> Ectopic endometrial glands in myometrium; enlarged, boggy, uniformly |
- | tender uterus with menorrhagia and severe dysmenorrhea |
- | L - LEIOMYOMA -> Uterine fibroids (Submucosal causing profound menorrhagia/anemia; |
- | Subserosal/Intramural causing bulk symptoms); firm, irregular uterus |
- | M - MALIGNANCY -> Endometrial hyperplasia or adenocarcinoma; cervical carcinoma |
- | |
- | [NON-STRUCTURAL CAUSES (COEIN) - Laboratory / Endocrine / Clinical Etiologies] |
- | C - COAGULOPATHY -> von Willebrand disease (heavy menses since menarche), thrombocytopenia |
- | O - OVULATORY -> Anovulatory bleeding: PCOS, thyroid disease, hyperprolactinemia, obesity |
- | E - ENDOMETRIAL -> Primary disorder of local endometrial hemostatic mechanisms (PGF2a/PGE2) |
- | I - IATROGENIC -> IUDs, subdermal implants, anticoagulants, psychotropic drugs |
- | N - NOT CLASSIFIED -> Arteriovenous malformations, rare vascular lesions |
- +---------------------------------------------------------------------------------------------------+
- Workup and Management of Postmenopausal Bleeding (PMB)
Postmenopausal vaginal bleeding is Endometrial Cancer until proven otherwise! Any vaginal bleeding occurring ≥ 12 months \ge 12\text{ months} ≥ 12 months after the final menstrual period demands immediate objective diagnostic investigation. +---------------------------------------------------------------------------------------------------+
- | POSTMENOPAUSAL UTERINE BLEEDING WORKUP ALGORITHM |
- | |
- | [POSTMENOPAUSAL PATIENT PRESENTS WITH EPISODIC OR CONTINUOUS UTERINE BLEEDING] |
- | | |
- | v |
- | [TRANSVAGINAL ULTRASOUND (TVUS) - FIRST-LINE NON-INVASIVE ASSESSMENT] |
- | - Measure Endometrial Thickness (EMT) double-layer stripe in the sagittal plane. |
- | | |
- | +------------------------+------------------------+ |
- | | | |
- | v v |
- | [EMT ≤ 4.0 mm] [EMT > 4.0 mm OR FLUID/HETEROGENEITY] |
- | - Negative predictive value for - High risk for hyperplasia / cancer. |
- | endometrial cancer >99%. - IMMEDIATE ACTION: Perform Gold-Standard |
- | - Management: Clinical observation. OFFICE PIPELLE ENDOMETRIAL BIOPSY (EMB). |
- | - Caveat: If bleeding recurs or - If EMB is non-diagnostic or bleeding |
- | persists -> MUST PROCEED TO EMB! persists -> Proceed to Hysteroscopy + D&C. |
- +---------------------------------------------------------------------------------------------------+
- 4. Cervical Cancer Screening & 2019/2020 ASCCP Risk Guidelines
A. USPSTF Cervical Cancer Screening Recommendations (Average-Risk Women) +---------------------------------------------------------------------------------------------------+
- | USPSTF CERVICAL CANCER SCREENING SCHEDULE |
- | |
- | AGE GROUP RECOMMENDED SCREENING STRATEGY USPSTF GRADE |
- | --------------------------------------------------------------------------------------------- |
- | <21 years DO NOT SCREEN (regardless of sexual history) Grade D (Discouraged) |
- | |
- | 21 - 29 years Cervical Cytology (Pap Smear) alone EVERY 3 YEARS Grade A (Recommended) |
- | (Do NOT screen with hrHPV co-testing or primary HPV) |
- | |
- | 30 - 65 years THREE ACCEPTABLE EVIDENCE-BASED STRATEGIES: Grade A (Recommended) |
- | 1. High-Risk HPV (hrHPV) alone EVERY 5 YEARS, OR |
- | 2. hrHPV + Cytology Co-Testing EVERY 5 YEARS, OR |
- | 3. Cervical Cytology alone EVERY 3 YEARS |
- | |
- | >65 years DISCONTINUE SCREENING IF adequate prior negative Grade D (Discouraged) |
- | screening AND no history of CIN 2, CIN 3, or AIS |
- | in the past 25 years. |
- | (Adequate prior negative: 3 consecutive negative Pap |
- | smears OR 2 consecutive negative co-tests in last 10 |
- | years, with the most recent test within 5 years). |
- | |
- | Post-Total DISCONTINUE SCREENING IF cervix removed for benign Grade D (Discouraged) |
- | Hysterectomy indications and no history of CIN 2+ or cancer. |
- +---------------------------------------------------------------------------------------------------+
- B. ASCCP 2019/2020 Risk-Based Consensus Guidelines
The American Society for Colposcopy and Cervical Pathology (ASCCP) shifted management from rigid test-result algorithms to individualized risk-based thresholds , estimating immediate and 5-year risk of Cervical Intraepithelial Neoplasia Grade 3 or worse (CIN 3+) . +---------------------------------------------------------------------------------------------------+
- | ASCCP RISK-BASED CLINICAL ACTION THRESHOLDS |
- | |
- | ESTIMATED IMMEDIATE RISK OF CIN 3+ MANDATED CLINICAL ACTION |
- | --------------------------------------------------------------------------------------------- |
- | Immediate Risk ≥ 60% Expedited Treatment (LEEP) or Colposcopy |
- | Immediate Risk 25% to 59% Expedited Treatment (LEEP) or Colposcopy |
- | Immediate Risk 4.0% to 24% COLPOSCOPY MANDATED |
- | Immediate Risk < 4.0% SURVEILLANCE (Return at 1, 3, or 5 years) |
- | - 5-year risk ≥ 0.55% -> 1-year follow-up (repeat hrHPV / co-testing) |
- | - 5-year risk 0.15% to 0.54% -> 3-year follow-up |
- | - 5-year risk < 0.15% -> 5-year routine return |
+---------------------------------------------------------------------------------------------------+ +---------------------------------------------------------------------------------------------------+
- | PRACTICAL CLINICAL ASCCP MANAGEMENT PATHWAYS |
- | |
- | 1. HPV 16 or HPV 18 POSITIVE (Any Cytology): |
- | - HPV 16/18 are responsible for 70% of invasive cervical cancers. |
- | - ACTION: Immediate COLPOSCOPY regardless of whether cytology is normal or abnormal. |
- | |
- | 2. HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL): |
- | - Immediate CIN 3+ risk exceeds 25%. |
- | - ACTION: COLPOSCOPY or direct EXPEDITED TREATMENT (LEEP excisional procedure). |
- | |
- | 3. ATYPICAL SQUAMOUS CELLS - CANNOT EXCLUDE HIGH-GRADE (ASC-H): |
- | - High risk of underlying high-grade dysplasia. |
- | - ACTION: Immediate COLPOSCOPY. |
- | |
- | 4. ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE (ASC-US): |
- | - Reflex hrHPV Negative -> Repeat Cytology / Co-testing in 3 YEARS. |
- | - Reflex hrHPV Positive -> Immediate COLPOSCOPY. |
- | |
- | 5. LOW-GRADE SQUAMOUS INTRAEPITHELIAL LESION (LSIL): |
- | - LSIL with hrHPV Positive -> Immediate COLPOSCOPY. |
- | - LSIL with hrHPV Negative -> Repeat Co-testing in 1 YEAR. |
- | |
- | 6. hrHPV POSITIVE WITH NORMAL (NILM) CYTOLOGY (Age ≥30): |
- | - Option A: Reflex Genotyping for HPV 16/18. If 16/18 positive -> COLPOSCOPY; if 16/18 negative|
- | -> Repeat Co-testing in 1 YEAR. |
- | - Option B: Repeat Co-testing in 1 YEAR. If persistent hrHPV+ or abnormal cytology at 1 year |
- | -> COLPOSCOPY. |
- +---------------------------------------------------------------------------------------------------+
- 5. Gynecologic Oncology Red Flags: Ovarian & Endometrial Cancer
Malignancy Cardinal Epidemiology & Risk Factors Hallmark Symptoms & Physical Exam Diagnostic Strategy & Screening Rules
Endometrial Cancer Most common GYN cancer; unopposed estrogen, obesity ( B M I ≥ 30 BMI \ge 30 BM I ≥ 30 ), nulliparity, PCOS, Tamoxifen, Lynch syndrome. Postmenopausal bleeding (PMB) ; abnormal intermenstrual or heavy prolonged bleeding. Transvaginal ultrasound ( E M T > 4 mm EMT >4\text{ mm} EMT > 4 mm triggers biopsy); Pipelle Endometrial Biopsy is definitive. NO routine screening.
Ovarian Cancer Highest mortality GYN cancer; age > 60 >60 > 60 , BRCA1/2 mutations, Lynch syndrome, nulliparity, family history. Non-specific: Persistent abdominal bloating, pelvic fullness, early satiety, urinary urgency > 2 − 3 >2-3 > 2 − 3 weeks; fixed solid adnexal mass. Transvaginal ultrasound + Serum CA-125. USPSTF Grade D: DO NOT screen asymptomatic average-risk women with CA-125/TVUS.
Cervical Cancer Persistent high-risk HPV (16, 18, 31, 33, 45), immunosuppression/HIV, tobacco smoking, high parity. Postcoital vaginal bleeding, watery malodorous bloody discharge, visible friable exophytic cervical mass. ASCCP guideline-directed Cytology/hrHPV screening; Colposcopy with targeted cervical biopsies.
6. Board-Yield Summary & Clinical Pearls +---------------------------------------------------------------------------------------------------+
- | ANCC AGPCNP CLINICAL EXAM PEARLS |
- | |
- | - Bacterial Vaginosis shows clue cells and elevated pH (>4.5) with NO white blood cells (WBCs); |
- | Trichomoniasis shows motile flagellated organisms, elevated pH (>4.5), and ABUNDANT WBCs. |
- | |
- | - Always treat Trichomoniasis with METRONIDAZOLE 500 mg PO BID for 7 days in women (not single |
- | dose), and ALWAYS treat the sexual partner concurrently! |
- | |
- | - Empiric PID outpatient regimen: CEFTRIAXONE 500 mg IM x 1 + DOXYCYCLINE 100 mg PO BID x 14 d |
- | + METRONIDAZOLE 500 mg PO BID x 14 d. Mandate clinical re-evaluation in 48-72 hours. |
- | |
- | - Postmenopausal uterine bleeding is ENDOMETRIAL CANCER until proven otherwise. Endometrial |
- | stripe thickness ≤4 mm on TVUS rules out cancer with >99% NPV; >4 mm requires Pipelle Biopsy. |
- | |
- | - Cervical screening NEVER begins before age 21 regardless of sexual debut (Grade D). |
- | |
- | - Any positive HPV 16 or HPV 18 test mandates immediate COLPOSCOPY regardless of Pap cytology! |
- | |
- | - Ovarian cancer screening with CA-125 or pelvic ultrasound in asymptomatic average-risk women |
- | is strictly HARMFUL and contraindicated (USPSTF Grade D). |
- +---------------------------------------------------------------------------------------------------+